Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 3Unspecified Adult Solid Tumor, Protocol Specific 1Resectable Pancreatic Carcinoma 1Rectal Neoplasms 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Breast Neoplasms 1Adenocarcinoma of the Pancreas 1

Interventions

Fluorouracil 38Capecitabine 31Oxaliplatin 30Leucovorin 30Radiotherapy 21Irinotecan 20Bevacizumab 15Radiation 12Cetuximab 12pembrolizumab 9Gemcitabine 7trifluridine tipiracil drug combination 5dehydroftorafur 5cediranib 5Radiotherapy, Intensity-Modulated 5Folfox protocol 5Erlotinib Hydrochloride 5Cisplatin 5Carboplatin 5trametinib 4Surgical Procedures, Operative 4Paclitaxel 4Neoadjuvant Therapy 4Gene Expression Profiling 4Cyclophosphamide 4sargramostim 3binimetinib 3Trifluridine 3Sorafenib 3Pemetrexed 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Rectal Neoplasms × paricalcitol × Clear all
NCT01197664 2018-07-02

Paricalcitol, Fluorouracil, and Radiation Therapy in Treating Patients With Rectal Cancer That Can Be Removed in Surgery

Wake Forest University Health Sciences

Phase 1 Terminated
2 enrolled
Gastrointestinal

Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡